Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNNMedical - Instruments & Supplies
+$0.37 today
- Market cap
- $158.01M
- Beta
- 4.34
- P/E (TTM)
- 99.1
- EPS (TTM)
- $0.16
Volume 0.09M
Average 0.03M
NNNN Other Financing Activities
Financing cash flows not reported separately.
Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN
Other Financing Activities · Q4 FY2024 · quarter ended Dec 2024
Other financing activities outflow grows to $0
Q4 FY2024 other financing activities was $0, compared with $0 a year earlier.
Context
- Other financing activities amounted to 2.9% of revenue in FY2025, down 1.3 pp from a year earlier.
- Other financing activities increased in 1 of the last 3 fiscal years.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- (282.55K) USD
- Year-over-year change
- +18.0%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (282.55K) | +18.0% |
| FY2024 | 2024-12-31 | (344.61K) | -704.5% |
| FY2023 | 2023-12-31 | (42.84K) | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Financing Activities vs competitors
How NNNN compares with its peers on the latest reported figures
- Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -18.0% is the 6th highest of 9, against a peer median of -3.0%.
- Other financing activities amounts to 2.9% of revenue for NNNN, versus a peer median of 0.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $186M USD | +32.9% | +9.7% | 0.9% | |
| LTM Mar 2026 | $3.23M USD | -62.6% | — | 1.1% | |
| LTM Mar 2026 | $2.89M USD | +4.0% | +21.8% | 1.2% | |
| LTM Mar 2026 | $2.54M USD | -77.7% | +76.8% | 6.3% | |
| LTM Mar 2026 | CA$834K CAD | -10.0% | -77.5% | 0.1% | |
| LTM Feb 2026 | $295K USD | +105.9% | — | 0.1% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | FY2025 | $282.55K USD | -18.0% | — | 2.9% |
| LTM Mar 2026 | $115.87K USD | -63.1% | — | — | |
| LTM Dec 2025 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | +100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding NNNN) | — | -3.0% | +15.7% | 0.1% | |
Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 2.54M | 10.01M | 2.25M | 2.37M | 6.4M |
| Depreciation & Amortization | 0 | 6.25K | 12.06K | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | 1.65M | (5.53M) | (1.2M) | 44.65K | (13.21M) |
| Accounts Receivables | (717.5K) | 717.5K | (1.88M) | 820.17K | (2.59M) |
| Inventory | 0 | (353.87K) | 353.87K | 0 | 0 |
| Accounts Payables | 1.89M | (481.82K) | (580.89K) | 798.1K | (1.63M) |
| Other Working Capital | 473.15K | (5.41M) | 907.97K | (1.57M) | (8.99M) |
| Other Non-Cash Items | 1 | (40.87K) | (163.39K) | (337.1K) | 68K |
| Operating Cash Flow | 4.18M | 4.45M | 898.37K | 2.08M | (6.74M) |
| Capital Expenditures | 0 | (3) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (16.09M) | (18.54M) | (35.47M) | (19.42M) |
| Sales of Investments | 0 | 14.56M | 20.27M | 35.8M | 15.22M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (1.53M) | 1.73M | 337.1K | (4.2M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 7.23M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (42.84K) | (344.61K) | (282.55K) |
| Financing Cash Flow | 0 | 0 | (42.84K) | (344.61K) | 6.95M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 4.18M | 2.92M | 2.59M | 2.07M | (3.99M) |
| Free Cash Flow | 4.18M | 4.45M | 898.37K | 2.08M | (6.74M) |
Anbio Biotechnology Class A Ordinary Shares
NASDAQ:NNNN
Intrinsic Alpha fair value
Locked
Current Price
$3.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.